Elevated levels of circulating cell-free DNA are found in advanced cancer stages, also in lung cancer patients. Assessment of this cfDNA in plasma of our patients was performed with the help of detection of some specific mutations EGFR,KRAS both in tumour tissue and in plasmatic cfDNA.
CfDNA should be used for investigation of methylation aberrations of tumour burden.